Is the price fair?
What BSX's price assumes
Boston Scientific trades at 19.5× earnings against 33.4× for the median Medical Devices name, cheaper than its own group.
19.5
Trailing P/E · Medical Devices median 33.4 · cheaper than the typical name in its group
- Price / sales
- 4.55
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.4%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +4.7%
Growth the price implies · The price pays for +4.7% free cash flow growth a year for a decade; the business has delivered +34% a year over the last three.
Details›
- Price / book2026-Q1
- 3.63
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $3.63B
- Market capitalisation
- $67.3B
- 3-year revenue growth
- +16%
- 3-year free cash flow growth
- +34%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $115.74 |
| Its own P/E history, median | $161.09 |
| Its own P/E history, upper quartile | $183.70 |
| 52-week range | $42.63 – $108.14 |
| Today | $48.18 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #24 of 35 by Smart Score